On January 10, 2022 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, reported a corporate update and highlighted key 2022 milestones in anticipation of its presentation at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10 – 13, 2022 (Press release, Nuvation Bio, JAN 10, 2022, View Source [SID1234598552]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are proud of the significant strides Nuvation Bio made in 2021, including the ongoing progress of our Phase 1/2 study of NUV-422 in patients with high-grade glioma, hormone receptor-positive metastatic breast cancer, and metastatic castration-resistant prostate cancer. Since the trial initiated, the FDA has cleared three INDs for NUV-422 and granted it Fast Track Designation for the treatment of high-grade glioma, demonstrating the therapy’s broad potential to address the significant unmet needs of patients with a variety of cancer types," said David Hung, M.D., founder, president, and chief executive officer of Nuvation Bio. "We look forward to building upon this momentum in 2022 with advancements across our deep pipeline of treatments for the most difficult-to-treat cancers."
In 2022, Nuvation Bio seeks to achieve the following milestones across its broad pipeline of potential product candidates:
NUV-422, CDK 2/4/6: High-grade glioma, aBC, mCRPC
Identify a recommended Phase 2 dose and initiate Phase 2 monotherapy dose expansion cohorts for NUV-422 in glioblastoma multiforme, advanced breast cancer (aBC), and metastatic castration-resistant prostate cancer (mCRPC)
Initiate Phase 1b combination studies for NUV-422 in aBC and mCRPC
Present safety data from NUV-422 Phase 1 dose escalation study
NUV-868, BD2 Selective BETi: Solid tumors
Receive clearance from U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application for NUV-868 and initiate a Phase 1 study in patients with advanced solid tumors
NUV-569, Wee1i: Solid tumors
File an IND for NUV-569 with the FDA for the treatment of patients with solid tumors
A2A and DDC Programs
Select clinical candidates
Presentation at J.P. Morgan Healthcare Conference
David Hung, M.D., founder, president, and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 a.m. ET. The presentation will be webcast live and can be accessed under "Events & Presentations" in the "Investors" section of Nuvation Bio’s website at www.nuvationbio.com.